Literature DB >> 15939071

High cumulative insulin exposure: a risk factor of atherosclerosis in type 1 diabetes?

Marian J Muis1, Michiel L Bots, Henk J G Bilo, Roel P L M Hoogma, Joost B L Hoekstra, Diederick E Grobbee, Ronald P Stolk.   

Abstract

BACKGROUND: Since insulin therapy might have an atherogenic effect, we studied the relationship between cumulative insulin dose and atherosclerosis in type 1 diabetes. We have focused on patients with type 1 diabetes instead of type 2 diabetes to minimise the effect of insulin resistance as a potential confounder.
METHODS: An observational study was performed in 215 subjects with type 1 diabetes treated with multiple insulin injection therapy. Atherosclerosis was assessed by measurement of carotid intima-media thickness (CIMT).
RESULTS: The cumulative dose of regular insulin showed a positive and significant relation with CIMT: increase of 21 microm in CIMT per S.D. of insulin use (95% CI: 8-35 adjusted for gender and age), which remained unchanged after adjustment for duration of diabetes, HbA1c, BMI, pulse pressure, physical activity and carotid lumen diameter. A similar relation was found for intermediate-acting insulin: 15.5 microm per S.D. (2-29), which was no longer present after further adjustment.
CONCLUSIONS: These findings provide evidence that a high cumulative dose of regular insulin is a risk factor for atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15939071     DOI: 10.1016/j.atherosclerosis.2005.01.004

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

Review 1.  Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.

Authors:  Rimke C Vos; Mariëlle Jp van Avendonk; Hanneke Jansen; Alexander N Goudswaard; Maureen van den Donk; Kees Gorter; Anneloes Kerssen; Guy Ehm Rutten
Journal:  Cochrane Database Syst Rev       Date:  2016-09-18

2.  Relationship of glycemic control, exogenous insulin, and C-peptide levels to ischemic heart disease mortality over a 16-year period in people with older-onset diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR).

Authors:  Flavio E Hirai; Scot E Moss; Barbara E K Klein; Ronald Klein
Journal:  Diabetes Care       Date:  2007-11-19       Impact factor: 19.112

3.  Chronic insulin treatment suppresses PTP1B function, induces increased PDGF signaling, and amplifies neointima formation in the balloon-injured rat artery.

Authors:  Qinghua Pu; Yingzi Chang; Chunxiang Zhang; Yi Cai; Aviv Hassid
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-11-14       Impact factor: 4.733

4.  The association between C-reactive protein levels and insulin therapy in obese vs nonobese veterans with type 2 diabetes mellitus.

Authors:  Sameed Ahmed M Khatana; Tracey H Taveira; Andrea G Dooley; Wen-Chih Wu
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-06       Impact factor: 3.738

5.  Age, gender, insulin and blood glucose control status alter the risk of ischemic heart disease and stroke among elderly diabetic patients.

Authors:  Toshio Hayashi; Seinosuke Kawashima; Hideki Nomura; Hideki Itoh; Hiroshi Watanabe; Takashi Ohrui; Koutaro Yokote; Hirohito Sone; Yoshiyuki Hattori; Masao Yoshizumi; Koichiro Ina; Kiyoshi Kubota
Journal:  Cardiovasc Diabetol       Date:  2011-10-06       Impact factor: 9.951

6.  Efficacy and Safety of Premixed Human Insulin Combined with Sulfonylureas in Type 2 Diabetic Patients Previously Poorly Controlled with Insulin.

Authors:  Ying-Hua Chen; Hui-Zhi Li; Zhao-Sheng Tang; Lei Xu; Hua Wang; Bo Feng
Journal:  Diabetes Ther       Date:  2019-01-18       Impact factor: 2.945

7.  Early signs of atherosclerosis are associated with insulin resistance in non-obese adolescent and young adults with type 1 diabetes.

Authors:  Björn Rathsman; Stefan Rosfors; Ake Sjöholm; Thomas Nyström
Journal:  Cardiovasc Diabetol       Date:  2012-11-27       Impact factor: 9.951

8.  Changes in glucose and fat metabolism in response to the administration of a hepato-preferential insulin analog.

Authors:  Dale S Edgerton; Mary C Moore; Jason J Winnick; Melanie Scott; Ben Farmer; Helle Naver; Claus B Jeppesen; Peter Madsen; Thomas B Kjeldsen; Erica Nishimura; Christian L Brand; Alan D Cherrington
Journal:  Diabetes       Date:  2014-06-19       Impact factor: 9.461

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.